Cloverleaf Bio
PrivateLast Round
Seed
Sep 8, 2026
Total Funding Raised
$33.76M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Cloverleaf Bio is a biotechnology company developing a novel class of engineered tRNA-based therapeutics for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cloverleaf Bio Comparables
Compare Cloverleaf Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 81% | |
| Shape Therapeutics | 78% | |
| Tevard Biosciences | 78% |
Cloverleaf Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 8, 2026 | ||||
| Grant | Sep 15, 2025 | ||||
| Grant | Jun 23, 2025 | ||||
| Accelerator | Oct 30, 2024 |
Cloverleaf Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Threshold Ventures | Seed |
| 4BIO Capital | Seed |
| AbbVie Ventures | Seed |
| BrightEdge | Seed |
| Draper Associates | Seed |
| Boehringer Ingelheim Venture Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Open roles increased from 0 to 2, representing 40% of headcount.
- Sep 8, 2026
$33M round led by 4BIO Capital.
Recent news
Latest coverage and updates
- is_developingSep 15, 2026
Cloverleaf Bio is developing therapies based on transfer RNA, or tRNA on Sep 15th '26.
- receives_financingSep 8, 2026
Cloverleaf Bio received financing of $33M in Seed on Sep 8th '26.
Cloverleaf Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cloverleaf Bio's valuation, stock price, and market status.
Is Cloverleaf Bio a public or private company?
Cloverleaf Bio is a private company.
What is the current stock price of Cloverleaf Bio?
Cloverleaf Bio is a private company with no public stock price. Caplight tracks Cloverleaf Bio's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Cloverleaf Bio worth (valuation)?
Valuation information for Cloverleaf Bio is not publicly available.
Can I buy Cloverleaf Bio stock?
Cloverleaf Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cloverleaf Bio's last funding round?
Cloverleaf Bio's most recent funding round was Seed on September 8, 2026.
Who are the main investors in Cloverleaf Bio?
Key investors in Cloverleaf Bio include 4BIO Capital.
Will Cloverleaf Bio IPO soon?
No public IPO plans have been announced for Cloverleaf Bio.
How can I track Cloverleaf Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cloverleaf Bio's secondary market activity and sign up for updates.